Recombinant Proteins Market: By Product (Hormone, Growth Factor, Cytokines, Enzymes, Others), By Application (Research Application, Therapeutic Use, Biotechnology Industry), and Geography

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Recombinant Proteins Market is expected to be worth USD 1,926.1 million in 2022 and is projected to grow at a 3.1% CAGR from 2023 to 2029. Proteins encoded by a gene (recombinant DNA) and cloned in a prokaryotic system are known as prokaryotic recombinant proteins (E.coli). Prokaryotic recombinant proteins are good candidates for chronic treatments and numerous autoimmune illnesses due to their high specificity and low immunogenicity. Monoclonal antibodies account for the majority of the recombinant protein market. chronic kidney disease (CKD) drugs (diabetes, cancer, cardiovascular disease, and others) will be the seventh biggest cause of death worldwide by 2030, according to the World Health Organization (WHO). This will fuel the expansion of the prokaryotic recombinant protein market because of its superior benefits and low side effects in treating chronic and autoimmune disorders. In terms of application, the global recombinant proteins market can be divided into Research Applications, Therapeutic Use, and Biotechnology Industry. The Therapeutic Use segment is anticipated to grow at a significant CAGR over the forecast years owing to recombinant protein-containing products used to treat diseases such as diabetes, cancer, and inflammatory diseases. An increase in the incidence of such diseases is likely to increase the demand for new treatment options. According to International Diabetes Federation, in 2019, approx. 463 million adults (20-79 years) were living with diabetes, and this value is projected to reach 700 million by 2045. Rising demand for therapeutics and the increasing use of recombinant proteins in treating diseases such as hemophilia are anticipated to positively influence the recombinant protein therapeutics market over the years to come.

Recombinant Proteins Market Key Developments:

  • In March 2022, Fujifilm Corporation has acquired Shenandoah Biotechnology, Inc., one of the leading manufacturers of recombinant proteins.
  • In January 2022, Thermo Fisher Scientific Inc. acquired PeproTech, Inc., one of the leading developers and manufacturers of recombinant proteins, for a total cash purchase price of approximately USD 1.85 billion.

Recombinant Proteins Market Summary

Study Period


Base Year




Largest Market

North America

Fastest Growing Market

Asia Pacific
Recombinant Proteins Market Dynamics

Due to protracted research and approval procedures, the R&D sector has always remained capital-intensive. Governments see R&D as essential to a country's progress, international competitiveness, and public benefit. Due to which, R&D spending and funding have steadily increased. The 2019 Global R&D Funding Forecast predicts that global life science R&D investment will increase by 3.6% to USD 2.3 trillion by 2019. While the industry is the primary source of R&D financing, academia is also important because research articles are written by academics.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Recombinant Proteins Market Segmentation

By Product
  • Hormone
  • Growth Factor
  • Cytokines
  • Enzymes
  • Others
By Application
  • Research Application
  • Therapeutic Use
  • Biotechnology Industry
By Geography
  • North America
  • Europe
  • The Asia Pacific
  • Latin America
  • MEA


Frequently Asked Questions

The global recombinant proteins market size is expected to be worth USD 1,926.1 million in 2022 and is projected to grow at a 3.1% CAGR from 2023 to 2029.

Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., Novo Nordisk A/S, Eli Lilly and Company., Merck KGaA, Abcam PLC, Amgen Inc., Sanofi SA, and Enzo Life Sciences, Inc are the key players in the market

Market growth is primarily driven by factors such as increasing government investments and R&D expenditure in pharmaceutical & biotechnology companies, growing industry-academia collaborations, and the patent expiry of biologics.

Research Application is the leading application segment in the market.

  • Bio-Rad Laboratories, Inc.,
  • Thermo Fisher Scientific, Inc.
  • Novo Nordisk A/S
  • Eli Lilly and Company.
  •  Merck KGaA
  • Abcam PLC
  • Amgen Inc.
  • Sanofi SA
  • Enzo Life Sciences, Inc